One mechanism that could explain this lower HNSCC incidence is the downregulation of cancer stemness and epithelial–mesenchymal transition-related genes, such as OCT4, SOX2 and NANOG, observed after metformin treatment, which could inhibit progression in cancer-initiating cells [110,111]. This evidence concerns the gene NANOG and cancer.